REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM) | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -2.29.

EBIT: As of FY2026 Q1, the actual value is USD -452.53 M.

Operational Metrics

• Research and Development Expenses
  • For the three months ended March 31, 2026, research and development expenses were $343,970 thousand, an increase from $205,749 thousand for the same period in 2025. This increase was primarily due to higher clinical trial and manufacturing expenses for daraxonrasib and zoldonrasib, increased personnel-related costs, and higher stock-based compensation expense .
• General and Administrative Expenses
  • General and administrative expenses for the three months ended March 31, 2026, were $101,252 thousand, compared to $35,011 thousand for the three months ended March 31, 2025. The rise was mainly attributed to higher stock-based compensation expense, increased personnel-related costs, commercial preparation activities, and higher administrative costs .
• Total Operating Expenses
  • Total operating expenses amounted to $445,222 thousand for the three months ended March 31, 2026, up from $240,760 thousand for the same period in 2025 .
• Loss from Operations
  • The company reported a loss from operations of - $445,222 thousand for the three months ended March 31, 2026, compared to - $240,760 thousand for the three months ended March 31, 2025 .
• Net Loss
  • Net loss for the three months ended March 31, 2026, was - $453,816 thousand, an increase from - $213,416 thousand for the three months ended March 31, 2025 .

Non-Operating Income (Expense), Net

• Interest Income
  • Interest income was $19,508 thousand for the three months ended March 31, 2026, and $24,915 thousand for the same period in 2025 .
• Interest Expense
  • Interest expense was - $12,197 thousand for the three months ended March 31, 2026, compared to $0 thousand for the three months ended March 31, 2025 .
• Change in Fair Value of Warrant Liability
  • The change in fair value of warrant liability was - $15,788 thousand in 2026, compared to $2,439 thousand in 2025 .
• Other Expense, Net
  • Other expense, net, was - $117 thousand in 2026 and - $10 thousand in 2025 .
• Total Non-Operating Income (Loss), Net
  • Total non-operating income (loss), net, was - $8,594 thousand for the three months ended March 31, 2026, versus $27,344 thousand for the three months ended March 31, 2025 .

Balance Sheet Metrics

• Cash, Cash Equivalents and Marketable Securities
  • As of March 31, 2026, cash, cash equivalents and marketable securities totaled $1,908,084 thousand, a decrease from $2,025,679 thousand as of December 31, 2025 .
• Working Capital
  • Working capital was $1,678,314 thousand as of March 31, 2026, down from $1,784,613 thousand as of December 31, 2025 .
• Total Assets
  • Total assets were $2,253,737 thousand as of March 31, 2026, compared to $2,354,508 thousand as of December 31, 2025 .
• Total Liabilities
  • Total liabilities increased to $753,820 thousand as of March 31, 2026, from $723,211 thousand as of December 31, 2025 .
• Total Stockholders’ Equity
  • Total stockholders’ equity was $1,499,917 thousand as of March 31, 2026, a decrease from $1,631,297 thousand as of December 31, 2025 .

Other Key Financial Indicators

• Stock-Based Compensation Expense
  • Stock-based compensation expense was $87.3 million in Q1 2026, significantly higher than $25.1 million in Q1 2025. An additional $44.6 million was recognized in Q1 2026 due to an updated equity compensation program that introduced retirement benefits .
• Financings
  • In April 2026, Revolution Medicines, Inc. secured $2.2 billion in gross proceeds from concurrent public offerings of common stock and convertible senior notes. The company received $2.1 billion in net proceeds from these financings .

Financial Guidance

Revolution Medicines, Inc. updated its full year 2026 GAAP operating expenses guidance to a range of $1.7 billion to $1.8 billion . The company now anticipates full year 2026 stock-based compensation expense to be between $260 million and $280 million . This revised stock-based compensation guidance reflects an approximately $80 million increase from previous estimates, driven by higher projected non-cash stock-based compensation expense .